Endocrine and metabolic responses to long-term monotherapy with the antiepileptic drug XXXX in the normally cycling @entity2608 .

@entity3610 @entity1420 @entity1092 @entity53 @entity4418 @entity2052 @entity302 @entity342 @entity1176 @entity2608 @entity2670 @entity413
An association between @entity302 and reproductive disturbances with an apparent increase in a @entity3610 ( @entity3610 ) has been reported. Whether this association can be attributed to @entity302 itself or is related to antiepileptic drug therapy, in particular @entity1092 ( @entity2052 ), remains controversial. We studied effects of a long-term @entity2052 treatment on cycling monkeys, postulating that, if @entity2052 monotherapy were to promote abnormal endocrine and metabolic parameters that are characteristic of @entity3610 , changes in cyclicity would be readily demonstrated. After a 2-month control, a 12- to 15-month @entity2052 monotherapy was initiated in 7 regularly cycling @entity2608 . Overall mean levels of @entity2052 were 88.7 +/- 4.0 (SE) microg/ml. Mean body weight increased progressively during @entity2052 treatment from 8.5 +/- 0.5 kg before treatment to 9.6 +/- 0.7 kg in the last week of treatment (P < 0.05). Monkeys continued to have regular ovulatory menstrual cycles throughout @entity2052 monotherapy. Length of the cycles was 28 +/- 0.58 d in control and 28.4 +/- 1.18 d in the last 3 months of @entity2052 treatment. Follicular and luteal lengths and peak preovulatory @entity53 and integrated luteal @entity1420 levels did not differ between control and treatment. Ovaries from @entity2052 -treated monkeys showed histological evidence of ovulation, and none had characteristic features of @entity3610 . Endocrine @entity3610 markers, such as increased early follicular LH/FSH ratio and @entity342 levels were not different in control and @entity2052 treatment cycles. LH and @entity4418 responses to @entity1176 agonist challenges and the insulin response to @entity413 tolerance tests were similar in control and @entity2052 groups. Lipid profiles were not affected by @entity2052 treatment. The data indicate that a 12- to 15-month therapeutic exposure to @entity2052 does not induce cyclic hormonal or morphological @entity2670 or characteristics of the @entity3610 when administered to nonepileptic normally cycling nonhuman primates.
